Jon CohenScience’s COVID-19 reporting is supported by the Pulitzer Center and the Heising-Simons Foundation.Not to be outdone by a rival with a similar product, Pfizer and BioNTech today provided an update on the previously announced success of their COVID-19 vaccine.
The U.S. pharma giant and its German biotech partner now report 95% efficacy for their vaccine candidate, drawing on the final analysis of a 43,000-person study.
And don’t worry about the elderly not responding to the vaccine; the efficacy only drops to 94% in people over 65 years of age, the companies said in a press release.As opposed to the vague initial report last week that their vaccine had greater than 90% efficacy, Pfizer and BioNTech are providing more specific data.